Labcorp Expands DPYD Genetic Test to Identify Chemotherapy Toxicity Risk in Cancer Patients

MT Newswires Live05-28

Labcorp (LH) said Thursday that it expanded its DPYD Genotyping test to help identify cancer patients at higher risk of severe side effects from fluoropyrimidine chemotherapy, including 5-fluorouracil and capecitabine.

The company said the updated test now covers all DPYD Tier 1 and Tier 2 genetic variants recommended by the Association for Molecular Pathology.

According to Labcorp, about 9% of patients carry DPYD variants that impair the body's ability to metabolize fluoropyrimidines, increasing the risk of toxic reactions such as neutropenia, diarrhea, and neurotoxicity. The company cited estimates linking 5-FU toxicity to roughly 1,300 deaths annually in the United States.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2638698345?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-28 19:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2638698345","market":"nz","top_or_hot":-1,"title":"Labcorp Expands DPYD Genetic Test to Identify Chemotherapy Toxicity Risk in Cancer Patients","media":"MT Newswires Live","content":"<html><body><p> Labcorp (LH) said Thursday that it expanded its DPYD Genotyping test to help identify cancer patients at higher risk of severe side effects from fluoropyrimidine chemotherapy, including 5-fluorouracil and capecitabine.</p><p>The company said the updated test now covers all DPYD Tier 1 and Tier 2 genetic variants recommended by the Association for Molecular Pathology.</p><p>According to Labcorp, about 9% of patients carry DPYD variants that impair the body's ability to metabolize fluoropyrimidines, increasing the risk of toxic reactions such as neutropenia, diarrhea, and neurotoxicity. The company cited estimates linking 5-FU toxicity to roughly 1,300 deaths annually in the United States.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Labcorp Expands DPYD Genetic Test to Identify Chemotherapy Toxicity Risk in Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLabcorp Expands DPYD Genetic Test to Identify Chemotherapy Toxicity Risk in Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-28 19:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Labcorp (LH) said Thursday that it expanded its DPYD Genotyping test to help identify cancer patients at higher risk of severe side effects from fluoropyrimidine chemotherapy, including 5-fluorouracil and capecitabine.</p><p>The company said the updated test now covers all DPYD Tier 1 and Tier 2 genetic variants recommended by the Association for Molecular Pathology.</p><p>According to Labcorp, about 9% of patients carry DPYD variants that impair the body's ability to metabolize fluoropyrimidines, increasing the risk of toxic reactions such as neutropenia, diarrhea, and neurotoxicity. The company cited estimates linking 5-FU toxicity to roughly 1,300 deaths annually in the United States.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2237438978.USD","symbol_name":"Amundi Funds US Pioneer A2 (C) USD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2638698345","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2638698345","pubTimestamp":1779968991,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Labcorp (LH) said Thursday that it expanded its DPYD Genotyping test to help identify cancer patients at higher risk of severe side effects from fluoropyrimidine chemotherapy, including 5-fluorouracil","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","BK4196":"保健护理服务","LU0048573561.USD":"FIDELITY AMERICA \"A\" (USD) INC","BK4550":"红杉资本持仓","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","LU0251131958.USD":"FIDELITY AMERICA \"A\" (USD) ACC","LU0251142724.SGD":"Fidelity America A-SGD","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","LH":"徕博科","BK4585":"ETF&股票定投概念","BK4588":"碎股","LU0742534661.SGD":"Fidelity America A-SGD (hedged)"},"translate_title":"Labcorp扩展DPYD基因检测以识别癌症患者的化疗毒性风险","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LH":1},"content_text":"Labcorp (LH) said Thursday that it expanded its DPYD Genotyping test to help identify cancer patients at higher risk of severe side effects from fluoropyrimidine chemotherapy, including 5-fluorouracil and capecitabine.The company said the updated test now covers all DPYD Tier 1 and Tier 2 genetic variants recommended by the Association for Molecular Pathology.According to Labcorp, about 9% of patients carry DPYD variants that impair the body's ability to metabolize fluoropyrimidines, increasing the risk of toxic reactions such as neutropenia, diarrhea, and neurotoxicity. The company cited estimates linking 5-FU toxicity to roughly 1,300 deaths annually in the United States.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2638698345","isCrawlerRequest":true}